Werewolf Therapeutics (NASDAQ:HOWL) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Werewolf Therapeutics (NASDAQ:HOWL) in a research report report published on Wednesday,Benzinga reports. The firm currently has a $15.00 price target on the stock.

Separately, JMP Securities dropped their price objective on Werewolf Therapeutics from $12.00 to $4.00 and set a “market outperform” rating for the company in a report on Tuesday, January 14th.

Werewolf Therapeutics Trading Down 2.4 %

Shares of HOWL stock opened at $1.23 on Wednesday. The stock has a market capitalization of $54.81 million, a PE ratio of -0.80 and a beta of 0.37. Werewolf Therapeutics has a 1-year low of $1.03 and a 1-year high of $6.89. The business has a 50-day moving average of $1.37 and a 200 day moving average of $1.82. The company has a debt-to-equity ratio of 0.29, a current ratio of 10.10 and a quick ratio of 10.10.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its earnings results on Tuesday, March 11th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.03). Werewolf Therapeutics had a negative net margin of 578.80% and a negative return on equity of 58.83%. As a group, sell-side analysts anticipate that Werewolf Therapeutics will post -1.56 earnings per share for the current year.

Institutional Investors Weigh In On Werewolf Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Walleye Capital LLC lifted its holdings in Werewolf Therapeutics by 10.7% in the 3rd quarter. Walleye Capital LLC now owns 108,968 shares of the company’s stock worth $231,000 after buying an additional 10,528 shares during the period. Regal Investment Advisors LLC lifted its holdings in Werewolf Therapeutics by 88.1% in the 4th quarter. Regal Investment Advisors LLC now owns 27,204 shares of the company’s stock worth $40,000 after buying an additional 12,745 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of Werewolf Therapeutics by 23.1% in the 4th quarter. Bank of New York Mellon Corp now owns 71,300 shares of the company’s stock valued at $106,000 after purchasing an additional 13,372 shares during the period. Geode Capital Management LLC lifted its stake in shares of Werewolf Therapeutics by 2.4% in the 4th quarter. Geode Capital Management LLC now owns 702,558 shares of the company’s stock valued at $1,040,000 after purchasing an additional 16,569 shares during the period. Finally, Northern Trust Corp lifted its stake in shares of Werewolf Therapeutics by 7.3% in the 4th quarter. Northern Trust Corp now owns 244,390 shares of the company’s stock valued at $362,000 after purchasing an additional 16,640 shares during the period. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.